US4804624A
(en)
*
|
1982-05-21 |
1989-02-14 |
The University Of Tennessee Research Corporation |
Passive agglutination assay for pseudorabies antibody
|
SE8205892D0
(sv)
*
|
1982-10-18 |
1982-10-18 |
Bror Morein |
Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
|
US4772466A
(en)
*
|
1983-08-22 |
1988-09-20 |
Syntex (U.S.A.) Inc. |
Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
|
US4770874A
(en)
*
|
1983-08-22 |
1988-09-13 |
Syntex (U.S.A.) Inc. |
Polyoxypropylene-polyoxyethylene block polymer based adjuvants
|
US5916588A
(en)
*
|
1984-04-12 |
1999-06-29 |
The Liposome Company, Inc. |
Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
|
US6090406A
(en)
*
|
1984-04-12 |
2000-07-18 |
The Liposome Company, Inc. |
Potentiation of immune responses with liposomal adjuvants
|
SE8402861L
(sv)
*
|
1984-05-28 |
1985-11-29 |
Stefan Svenson |
Rening av biologiskt material
|
NL8403195A
(nl)
*
|
1984-10-19 |
1986-05-16 |
Nederlanden Staat |
Immunogene complexen en vaccins die deze bevatten.
|
SE8405493D0
(sv)
*
|
1984-11-01 |
1984-11-01 |
Bror Morein |
Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
|
CA1267087A
(en)
*
|
1985-02-14 |
1990-03-27 |
Nicolaas Visser |
Synthetic immunogen
|
US4683294A
(en)
*
|
1985-04-03 |
1987-07-28 |
Smith Kline Rit, S.A. |
Process for the extraction and purification of proteins from culture media producing them
|
US4871488A
(en)
*
|
1985-04-22 |
1989-10-03 |
Albany Medical College Of Union University |
Reconstituting viral glycoproteins into large phospholipid vesicles
|
US4631191A
(en)
*
|
1985-06-20 |
1986-12-23 |
Biotechnology Research Partners, Ltd. |
Methods and compositions useful in preventing equine influenza
|
ATE71303T1
(de)
*
|
1986-01-14 |
1992-01-15 |
Nederlanden Staat |
Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
|
US4981685A
(en)
*
|
1986-03-07 |
1991-01-01 |
Utah State University Foundation |
Bacterial extract vaccines for veterinary application
|
US4806350A
(en)
*
|
1986-04-18 |
1989-02-21 |
Norden Laboratories, Inc. |
Vaccine formulation
|
CA1331355C
(en)
*
|
1986-04-21 |
1994-08-09 |
Bioenterprises Pty. Ltd |
Immunopotentation
|
ZA872203B
(en)
*
|
1986-04-28 |
1988-02-24 |
New York Blood Center Inc |
Complex immunogen containing synthetic peptides
|
JPH0789951B2
(ja)
*
|
1986-06-18 |
1995-10-04 |
財団法人阪大微生物病研究会 |
遺伝子発現産物の精製法
|
US5374426A
(en)
*
|
1986-09-03 |
1994-12-20 |
University Of Saskatchewan |
Rotavirus nucleocapsid protein VP6 in vaccine compositions
|
US5190859A
(en)
*
|
1987-02-26 |
1993-03-02 |
Dana-Farber Cancer Institute, Inc. |
Purification of LFA-3
|
US5026828A
(en)
*
|
1987-02-27 |
1991-06-25 |
Merck & Co., Inc. |
Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
|
US5976839A
(en)
*
|
1987-03-13 |
1999-11-02 |
Bioenterprises Pty Limited |
Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
|
US4888416A
(en)
*
|
1987-03-30 |
1989-12-19 |
International Minerals & Chemical Corp. |
Method for stabilizing somatotropins
|
US5583112A
(en)
*
|
1987-05-29 |
1996-12-10 |
Cambridge Biotech Corporation |
Saponin-antigen conjugates and the use thereof
|
US5043158A
(en)
*
|
1987-08-21 |
1991-08-27 |
Chembiomed, Ltd. |
Immunogenic compositions containing ordered carriers
|
US5011915A
(en)
*
|
1987-10-26 |
1991-04-30 |
Merck & Co., Inc. |
Process for purifying recombinant hepatitis antigens
|
WO1989005151A1
(en)
*
|
1987-12-04 |
1989-06-15 |
The Liposome Company, Inc. |
High integrity liposomes and method of preration and use
|
WO1989006658A1
(en)
*
|
1988-01-13 |
1989-07-27 |
The University Of North Carolina At Chapel Hill |
Immunogenic peptides
|
US5039522A
(en)
*
|
1988-01-29 |
1991-08-13 |
New York Blood Center, Inc. |
Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
|
US5885589A
(en)
*
|
1988-04-12 |
1999-03-23 |
Intervet International B.V. |
Pasteurella vaccine
|
DK199588D0
(da)
*
|
1988-04-12 |
1988-04-12 |
Nordisk Droge & Kemikalie |
Vaccine
|
AU638210B2
(en)
*
|
1988-05-04 |
1993-06-24 |
Dana-Farber Cancer Institute, Inc. |
Protein micelles
|
US5071964A
(en)
*
|
1988-05-04 |
1991-12-10 |
Dana-Farber Cancer Institute, Inc. |
Protein micelles
|
US6291228B1
(en)
*
|
1988-08-03 |
2001-09-18 |
Vericore Limited |
Vaccine
|
GB8818415D0
(en)
*
|
1988-08-03 |
1988-09-07 |
Animal Health Inst |
Vaccine
|
JPH0292996A
(ja)
*
|
1988-09-30 |
1990-04-03 |
Bror Morein |
アジュバントおよび脂質を含む複合体
|
NZ230747A
(en)
*
|
1988-09-30 |
1992-05-26 |
Bror Morein |
Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
|
US4981684A
(en)
*
|
1989-10-24 |
1991-01-01 |
Coopers Animal Health Limited |
Formation of adjuvant complexes
|
AU639719B2
(en)
*
|
1989-09-15 |
1993-08-05 |
Tanox Biosystems, Inc. |
Treatment of autoimmune disease
|
NL9002314A
(nl)
*
|
1990-10-23 |
1992-05-18 |
Nederlanden Staat |
Immunogene complexen, in het bijzonder iscoms.
|
IT1248075B
(it)
*
|
1991-06-18 |
1995-01-05 |
Sclavo Spa |
Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
|
GB9200117D0
(en)
*
|
1992-01-06 |
1992-02-26 |
Connaught Lab |
Production of recombinant chimeric proteins for vaccine use
|
DE4220653A1
(de)
*
|
1992-06-26 |
1994-01-13 |
Boehringer Mannheim Gmbh |
Verfahren und Mittel zum Nachweis eines Analyten enthaltend glykosidische Tenside
|
EP0604727A1
(en)
*
|
1992-12-31 |
1994-07-06 |
American Cyanamid Company |
Improved immunogenicity of a vaccine by incorporation of a cytokine within an immune-stimulating complex containing an antigen
|
EP0716697B1
(en)
*
|
1993-09-03 |
2003-04-02 |
McGILL UNIVERSITY |
DIFFERENTIALLY EXPRESSED $i(LEISHMANIA) GENES AND PROTEINS
|
US5773011A
(en)
*
|
1993-09-27 |
1998-06-30 |
Gerbu Biotechnik Gmbh |
Method of preparing a synergistic immunological adjuvant formulation
|
GB9320597D0
(en)
*
|
1993-10-06 |
1993-11-24 |
Proteus Molecular Design |
Improvements in and realting to vaccines
|
US6083513A
(en)
*
|
1993-11-16 |
2000-07-04 |
Gerbu Biotechnik Gmbh |
Method for increasing the yield of antibodies in the techniques of immunology
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
WO1996015807A1
(en)
*
|
1994-11-21 |
1996-05-30 |
Scofield Virginia L |
Sperm as vaccine vectors
|
CA2211650A1
(en)
*
|
1995-01-27 |
1996-08-01 |
Genencor International, Inc. |
Surfactant-based extraction process
|
DE69521533T2
(de)
*
|
1995-06-07 |
2001-10-04 |
Pfizer |
In ovo impfung gegen coccidiose
|
SK282004B6
(sk)
|
1995-06-07 |
2001-10-08 |
Pfizer Inc. |
Použitie živých sporozoitov alebo merozoitov rodu eimeria na výrobu očkovacej látky na in ovo očkovanie domestikovaných vtákov proti kokcidióze
|
ZA97452B
(en)
|
1996-01-25 |
1997-08-15 |
Trinity College Dublin |
Streptococcus equi vaccine.
|
GB9618119D0
(en)
*
|
1996-08-30 |
1996-10-09 |
Univ Southampton |
Adjuvants for use in vaccines
|
ZA9710606B
(en)
*
|
1996-12-05 |
1998-06-12 |
Akzo Nobel Nv |
Non-virulent Mycoplasma synoviae vaccine thereof.
|
US6406705B1
(en)
*
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
AUPO732997A0
(en)
|
1997-06-12 |
1997-07-03 |
Csl Limited |
Ganglioside immunostimulating complexes and uses thereof
|
US6455323B1
(en)
|
1997-07-03 |
2002-09-24 |
Pharmacia & Upjohn Company |
Anti-bacterial methods and materials
|
US6627205B2
(en)
|
1997-12-01 |
2003-09-30 |
Pfizer Incorporated |
Ovo vaccination against coccidiosis
|
US6495140B1
(en)
|
1998-01-12 |
2002-12-17 |
Her Majesty In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada |
Process for the isolation, recovery and purification of non-polar extractives
|
US6908770B1
(en)
*
|
1998-07-16 |
2005-06-21 |
Board Of Regents, The University Of Texas System |
Fluid based analysis of multiple analytes by a sensor array
|
US20010033839A1
(en)
*
|
1999-10-04 |
2001-10-25 |
Emilio Barbera-Guillem |
Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
|
GB2348203B
(en)
|
1998-11-04 |
2002-06-19 |
Imp College Innovations Ltd |
Solube beta-forms of prion proteins, methods of preparation and use
|
AU783344B2
(en)
*
|
1999-02-17 |
2005-10-20 |
Csl Limited |
Immunogenic complexes and methods relating thereto
|
US6984378B1
(en)
|
1999-02-26 |
2006-01-10 |
Pfizer, Inc. |
Method for the purification, recovery, and sporulation of cysts and oocysts
|
US6790950B2
(en)
|
1999-04-09 |
2004-09-14 |
Pharmacia & Upjohn Company |
Anti-bacterial vaccine compositions
|
JP4892134B2
(ja)
|
1999-04-09 |
2012-03-07 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
抗菌ワクチン組成物
|
DK1187629T3
(da)
|
1999-04-19 |
2005-01-17 |
Glaxosmithkline Biolog Sa |
Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
DE60036952T2
(de)
*
|
1999-09-24 |
2008-08-07 |
Glaxosmithkline Biologicals S.A. |
Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
|
AU772617B2
(en)
*
|
1999-11-19 |
2004-05-06 |
Csl Limited |
Vaccine compositions
|
WO2001070247A2
(en)
|
2000-03-17 |
2001-09-27 |
Pharmacia & Upjohn Company |
Salmonella vaccine materials and methods
|
WO2001077365A2
(en)
|
2000-04-06 |
2001-10-18 |
Pharmacia & Upjohn Company |
Antimicrobial methods and materials
|
US7323174B1
(en)
|
2000-06-12 |
2008-01-29 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Modulation of immune response and methods based thereon
|
ES2392943T3
(es)
|
2000-10-18 |
2012-12-17 |
Glaxosmithkline Biologicals S.A. |
Vacunas antitumorales
|
JP2004511527A
(ja)
*
|
2000-10-18 |
2004-04-15 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ワクチン
|
EP2269639B1
(en)
|
2001-02-23 |
2018-11-28 |
GlaxoSmithKline Biologicals s.a. |
Influenza vaccine formulations for intradermal delivery
|
NZ529347A
(en)
|
2001-04-04 |
2008-01-31 |
Nordic Vaccine Technology As |
Use of at least one sterol capable of interacting with a nucleic acid and at least saponin to form immunostimulating complexes ( IMSCO )
|
US7713942B2
(en)
*
|
2001-04-04 |
2010-05-11 |
Nordic Vaccine Technology A/S |
Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB0112126D0
(en)
|
2001-05-18 |
2001-07-11 |
Allergene Inc |
Composition
|
US20100221284A1
(en)
|
2001-05-30 |
2010-09-02 |
Saech-Sisches Serumwerk Dresden |
Novel vaccine composition
|
MY134424A
(en)
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
CN101381681B
(zh)
|
2001-08-30 |
2013-08-07 |
恩布里克斯公司 |
制备卵囊的改进方法
|
SE0202110D0
(sv)
*
|
2002-07-05 |
2002-07-05 |
Isconova Ab |
Iscom preparation and use thereof
|
JP2005535350A
(ja)
|
2002-08-12 |
2005-11-24 |
アクゾ・ノベル・エヌ・ベー |
ストレプトコッカス・ユベリス蛋白質、前記蛋白質をコードする核酸配列及び乳腺炎ワクチンにおけるその使用
|
AU2003274511B2
(en)
|
2002-10-11 |
2009-06-04 |
Glaxosmithkline Biologicals S.A. |
Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
|
US7125425B2
(en)
*
|
2002-10-21 |
2006-10-24 |
Sdgi Holdings, Inc. |
Systems and techniques for restoring and maintaining intervertebral anatomy
|
WO2004045641A2
(en)
|
2002-11-20 |
2004-06-03 |
Crucell Holland B.V. |
Antigen-complexes
|
US7491395B2
(en)
|
2002-11-20 |
2009-02-17 |
Bestewil Holding B.V. |
Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
|
CN102302776B
(zh)
|
2003-01-30 |
2014-06-18 |
诺华疫苗和诊断有限公司 |
抗多种脑膜炎球菌血清组的可注射性疫苗
|
AR056245A1
(es)
|
2003-06-19 |
2007-10-03 |
Bestewil Holding Bv |
Membranas virales reconstituidas funcionales que contienen un coadyuvante
|
US9023366B2
(en)
|
2003-07-01 |
2015-05-05 |
The Royal Veterinary College |
Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
|
GB0315323D0
(en)
|
2003-07-01 |
2003-08-06 |
Royal Veterinary College |
Vaccine composition
|
SE0301998D0
(sv)
|
2003-07-07 |
2003-07-07 |
Isconova Ab |
Quil A fraction with low toxicity and use thereof
|
ES2505695T3
(es)
|
2003-07-31 |
2014-10-10 |
Novartis Vaccines And Diagnostics, Inc. |
Composiciones inmunógenas para Streptococcus pyogenes
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
BRPI0415025A
(pt)
|
2003-10-02 |
2006-12-12 |
Chiron Srl |
vacinas lìquidas para sorogrupos meningocócicos múltiplos
|
US20080254065A1
(en)
|
2004-03-09 |
2008-10-16 |
Chiron Corporation |
Influenza Virus Vaccines
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
RU2379052C2
(ru)
|
2004-04-30 |
2010-01-20 |
Чирон С.Р.Л. |
Вакцинация менингококковыми конъюгатами
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
WO2006078294A2
(en)
|
2004-05-21 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Alphavirus vectors for respiratory pathogen vaccines
|
WO2005117958A1
(en)
|
2004-05-28 |
2005-12-15 |
Glaxosmithkline Biologicals S.A. |
Vaccine compositions comprising virosomes and a saponin adjuvant
|
JP2008506789A
(ja)
|
2004-07-18 |
2008-03-06 |
シーエスエル、リミテッド |
インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
|
JP2008508320A
(ja)
|
2004-07-29 |
2008-03-21 |
カイロン コーポレイション |
Streptococcusagalactiaeのようなグラム陽性細菌に対する免疫原性組成物
|
EP3312272B1
(en)
|
2004-10-08 |
2019-08-28 |
The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services |
Modulation of replicative fitness by using less frequently used synonymous codons
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
DK1838341T3
(da)
|
2005-01-20 |
2013-11-04 |
Isconova Ab |
Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
NZ560929A
(en)
|
2005-02-18 |
2009-12-24 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
HUE027400T2
(en)
|
2005-02-18 |
2016-10-28 |
Glaxosmithkline Biologicals Sa |
Proteins and nucleic acids from meningitis / sepsis with Escherichia coli
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
JP2008546658A
(ja)
|
2005-06-16 |
2008-12-25 |
ウニヴァシテイト ゲント |
ヘリコバクターに対する免疫化のためのワクチン
|
AU2006273753B2
(en)
|
2005-07-28 |
2010-06-24 |
Zoetis Services Llc |
Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline parvovirus and feline herpes virus
|
GB0519871D0
(en)
|
2005-09-30 |
2005-11-09 |
Secr Defence |
Immunogenic agents
|
JP4667507B2
(ja)
|
2005-10-07 |
2011-04-13 |
ファイザー・プロダクツ・インク |
イヌインフルエンザを治療するワクチンおよび方法
|
WO2007047749A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
PL2368572T3
(pl)
|
2005-11-04 |
2020-11-16 |
Seqirus UK Limited |
Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
|
CA2630220C
(en)
|
2005-11-22 |
2020-10-13 |
Doris Coit |
Norovirus and sapovirus antigens
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
PT1962899E
(pt)
|
2005-12-22 |
2011-10-19 |
Glaxosmithkline Biolog Sa |
Vacina conjugada polissacarídica pneumocócica
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP3753574A1
(en)
|
2006-01-27 |
2020-12-23 |
Seqirus UK Limited |
Influenza vaccines containing hemagglutinin and matrix proteins
|
EP2010537B1
(en)
|
2006-03-23 |
2011-12-28 |
Novartis AG |
Imidazoquinoxaline compounds as immunomodulators
|
CA2646891A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
WO2007110776A1
(en)
|
2006-03-24 |
2007-10-04 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Storage of influenza vaccines without refrigeration
|
EA020459B1
(ru)
|
2006-03-30 |
2014-11-28 |
Глаксосмитклайн Байолоджикалс С.А. |
Иммуногенная композиция
|
US20100285062A1
(en)
|
2006-03-31 |
2010-11-11 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
WO2008001224A2
(en)
|
2006-06-29 |
2008-01-03 |
Novartis Ag |
Polypeptides from neisseria meningitidis
|
EA200900033A1
(ru)
|
2006-07-18 |
2009-12-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Вакцины против малярии
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
US8323664B2
(en)
|
2006-07-25 |
2012-12-04 |
The Secretary Of State For Defence |
Live vaccine strains of Francisella
|
EP2064230A2
(en)
|
2006-08-16 |
2009-06-03 |
Novartis AG |
Immunogens from uropathogenic escherichia coli
|
NZ575271A
(en)
|
2006-09-11 |
2011-09-30 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
BRPI0716959A2
(pt)
|
2006-09-26 |
2013-10-29 |
Infectious Disease Res Inst |
Composição de vacina contendo adjuvante sintético
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
PL2121011T3
(pl)
|
2006-12-06 |
2014-10-31 |
Novartis Ag |
Szczepionki zawierające antygeny czterech szczepów wirusa grypy
|
ES2660035T3
(es)
|
2006-12-27 |
2018-03-20 |
Zoetis Services Llc |
Procedimiento de administración de vacuna
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
BRPI0811908A2
(pt)
|
2007-05-25 |
2014-11-18 |
Novartis Ag |
Antígenos de pilus de streptococcus pneumoniae
|
BRPI0813644B8
(pt)
|
2007-06-26 |
2021-05-25 |
Glaxosmithkline Biologicals Sa |
composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
|
CN101784283A
(zh)
|
2007-06-27 |
2010-07-21 |
诺华有限公司 |
低添加流感疫苗
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
CN101969992B
(zh)
|
2007-09-12 |
2014-10-01 |
诺华股份有限公司 |
Gas57突变型抗原和gas57抗体
|
EP2062594A1
(en)
|
2007-11-21 |
2009-05-27 |
Wyeth Farma, S.A. |
Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
AU2008352942B2
(en)
|
2007-12-19 |
2013-09-12 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
NZ586430A
(en)
|
2007-12-21 |
2012-09-28 |
Novartis Ag |
Mutant forms of streptolysin o (slo)
|
CA2710600C
(en)
|
2007-12-24 |
2017-06-06 |
Id Biomedical Corporation Of Quebec |
Recombinant rsv antigens
|
US9579372B2
(en)
|
2008-02-21 |
2017-02-28 |
Glaxosmithkline Biologicals Sa |
Meningococcal fHBP polypeptides
|
US20110014230A1
(en)
|
2008-03-18 |
2011-01-20 |
Novartis Ag |
preparation of influenza virus vaccine antigens
|
CN102481349B
(zh)
|
2009-01-12 |
2014-10-15 |
诺华股份有限公司 |
抗革兰氏阳性细菌疫苗中的Cna_B结构域
|
GB0900455D0
(en)
|
2009-01-13 |
2009-02-11 |
Secr Defence |
Vaccine
|
GB0901423D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
GB0901411D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
PE20110992A1
(es)
|
2009-02-17 |
2012-02-12 |
Glaxosmithkline Biolog Sa |
Composicion inmunogenica que comprende un antigeno del virus del dengue
|
CA2754618A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Ag |
Chlamydia antigens
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
EP2510947B1
(en)
|
2009-04-14 |
2016-02-10 |
GlaxoSmithKline Biologicals SA |
Compositions for immunising against Staphylococcus aureus
|
EP3124491B1
(en)
|
2009-06-05 |
2019-10-30 |
Infectious Disease Research Institute |
Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them
|
DK2442826T3
(en)
|
2009-06-15 |
2015-09-21 |
Univ Singapore |
Influenza vaccine, composition and methods of using
|
AU2010264686A1
(en)
|
2009-06-24 |
2012-01-19 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
EA023054B1
(ru)
|
2009-06-24 |
2016-04-29 |
Глэксосмитклайн Байолоджикалз С.А. |
Рекомбинантные антигены pcb
|
AU2010269148A1
(en)
*
|
2009-07-10 |
2012-01-19 |
Isconova Ab |
New composition
|
PL3178490T3
(pl)
|
2009-07-15 |
2022-08-01 |
Glaxosmithkline Biologicals S.A. |
Kompozycje białka f rsv i sposoby ich wytwarzania
|
CN102770443A
(zh)
|
2009-07-16 |
2012-11-07 |
诺华有限公司 |
脱毒大肠杆菌免疫原
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
NZ598458A
(en)
|
2009-08-27 |
2014-03-28 |
Novartis Ag |
Hybrid polypeptides including meningococcal fhbp sequences
|
US20110110980A1
(en)
|
2009-09-02 |
2011-05-12 |
Wyeth Llc |
Heterlogous prime-boost immunization regimen
|
SG178904A1
(en)
|
2009-09-10 |
2012-04-27 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
CN102724988B
(zh)
|
2009-09-30 |
2014-09-10 |
诺华股份有限公司 |
脑膜炎球菌fHBP多肽的表达
|
AU2010352695B2
(en)
|
2009-09-30 |
2014-08-21 |
Glaxosmithkline Biologicals S.A. |
Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
BR112012009309B1
(pt)
|
2009-10-19 |
2021-10-05 |
Intervet International B.V |
Vacina combinada, uso de células de microrganismos,método para a preparação de uma vacina combinada, e, kit de partes
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
JP2013507944A
(ja)
|
2009-10-22 |
2013-03-07 |
ウニヴェルシテート・ライプツィヒ |
汎血球減少症罹患仔ウシにおけるサーコウイルス(circovirus)の特定
|
JP5960055B2
(ja)
|
2009-10-27 |
2016-08-02 |
ノバルティス アーゲー |
改変髄膜炎菌fHBPポリペプチド
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
SG184188A1
(en)
|
2010-03-26 |
2012-10-30 |
Glaxosmithkline Biolog Sa |
Hiv vaccine
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011130379A1
(en)
|
2010-04-13 |
2011-10-20 |
Novartis Ag |
Benzonapthyridine compositions and uses thereof
|
EP2560985B1
(en)
|
2010-04-21 |
2016-06-29 |
Pharmaq AS |
Nucleic acid sequences of a fish virus and the use thereof
|
RU2636455C2
(ru)
|
2010-05-14 |
2017-11-23 |
Баксалта Инкорпорейтид, (US) |
Химерные гены ospa, белки и способы их применения
|
WO2011149564A1
(en)
|
2010-05-28 |
2011-12-01 |
Tetris Online, Inc. |
Interactive hybrid asynchronous computer game infrastructure
|
US9238796B2
(en)
|
2010-06-04 |
2016-01-19 |
Toagosei Co. Ltd. |
Cell growth-promoting peptide and use thereof
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
EP4008313A1
(en)
*
|
2010-06-24 |
2022-06-08 |
F. Hoffmann-La Roche AG |
Compositions and methods for stablizing protein-containing formulations
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
WO2012010290A1
(en)
|
2010-07-21 |
2012-01-26 |
Athera Biotechnologies Ab |
Diagnostic and therapeutic methods and compositions for metabolic disease
|
WO2012010291A1
(en)
|
2010-07-21 |
2012-01-26 |
Athera Biotechnologies Ab |
Diagnostic and therapeutic methods and compositions for metabolic disease
|
CN103052401A
(zh)
|
2010-07-23 |
2013-04-17 |
伊斯克诺瓦公司 |
流感疫苗
|
US8628947B2
(en)
|
2010-08-30 |
2014-01-14 |
Intervet Inc. |
Potomac horse fever isolates
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
EA201390452A1
(ru)
|
2010-09-27 |
2013-11-29 |
Глаксосмитклайн Байолоджикалс С.А. |
Вакцина
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
WO2012059592A1
(en)
|
2010-11-05 |
2012-05-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Compounds for delivering a therapeutic or imaging agent to the brain
|
CA2817933A1
(en)
|
2010-11-15 |
2012-05-24 |
Pharmaq As |
New salmon calicivirus isolate
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
AU2011340477A1
(en)
|
2010-12-08 |
2013-06-20 |
Neovacs |
Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
|
EP2462950A1
(en)
|
2010-12-08 |
2012-06-13 |
Neovacs |
Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
|
GB201022007D0
(en)
|
2010-12-24 |
2011-02-02 |
Imp Innovations Ltd |
DNA-sensor
|
CA2860331A1
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
EP2658568A1
(en)
|
2010-12-29 |
2013-11-06 |
Intervet International B.V. |
Canine babesiosis vaccine antigen
|
EP2658866B1
(en)
|
2010-12-29 |
2016-05-25 |
Intervet International B.V. |
Salmonid alphavirus protein e2
|
WO2012093706A1
(ja)
*
|
2011-01-07 |
2012-07-12 |
東亞合成株式会社 |
抗疎水性ペプチド抗体を得るための抗原調製方法
|
EP4144368A1
(en)
|
2011-01-26 |
2023-03-08 |
GlaxoSmithKline Biologicals S.A. |
Rsv immunization regimen
|
US20140086954A1
(en)
|
2011-03-31 |
2014-03-27 |
Chu De Toulouse |
Use of blood or tissue bacteriome for prediction, diagnosis and prevention of metabolic diseases and their cardiovascular complications
|
EP2508197A1
(en)
|
2011-04-07 |
2012-10-10 |
Neovacs |
Method for treating IFNalpha related conditions
|
BR112013025892B1
(pt)
|
2011-04-07 |
2021-01-19 |
Neovacs |
produto imunogênico, forma de dosagem unitária, dispositivo médico e kit relacionados a ifna
|
WO2012158613A1
(en)
|
2011-05-13 |
2012-11-22 |
Novartis Ag |
Pre-fusion rsv f antigens
|
CA2836098C
(en)
|
2011-05-13 |
2022-06-21 |
Zoetis Llc |
Hendra and nipah virus g glycoprotein immunogenic compositions
|
ES2656050T3
(es)
|
2011-07-06 |
2018-02-22 |
Glaxosmithkline Biologicals Sa |
Composiciones de combinación inmunogénica y usos de las mismas
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
US9149541B2
(en)
|
2011-07-08 |
2015-10-06 |
Novartis Ag |
Tyrosine ligation process
|
AU2012306282A1
(en)
|
2011-09-08 |
2014-03-20 |
Umc Utrecht Holding B.V. |
Vaccine based on Staphylococcal superantigen-like 3 protein (SSL3)
|
CN103917245B
(zh)
|
2011-09-14 |
2017-06-06 |
葛兰素史密丝克莱恩生物有限公司 |
用于制备糖‑蛋白质糖缀合物的方法
|
AU2012319239B2
(en)
|
2011-10-03 |
2017-04-20 |
Mx Adjuvac Ab |
Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
|
CN104080479B
(zh)
|
2011-11-07 |
2019-11-05 |
葛兰素史密丝克莱恩生物有限公司 |
包括spr0096和spr2021抗原的运载体分子
|
PL2782598T3
(pl)
|
2011-11-23 |
2021-03-08 |
In3Bio Ltd. |
Rekombinowane białka i ich zastosowania terapeutyczne
|
EP2785184B1
(en)
|
2011-11-30 |
2020-06-10 |
Emory University |
Compositions comprising jak inhibitors and haart drugs for use in the prevention or treatment of hiv
|
GB201200259D0
(en)
|
2012-01-09 |
2012-02-22 |
Ohlin Per M |
Novel therapies
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
PL2811981T3
(pl)
|
2012-02-07 |
2019-09-30 |
Infectious Disease Research Institute |
Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
|
NZ701881A
(en)
|
2012-05-16 |
2016-10-28 |
Immune Design Corp |
Vaccines for hsv-2
|
ES2820898T3
(es)
|
2012-05-22 |
2021-04-22 |
Glaxosmithkline Biologicals Sa |
Conjugado del serogrupo X de meningococos
|
US9370182B2
(en)
|
2012-05-28 |
2016-06-21 |
Toagosei Co., Ltd. |
Antimicrobial peptide and use thereof
|
WO2014005958A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
RU2015106742A
(ru)
|
2012-07-27 |
2016-09-20 |
Бакстер Интернэшнл Инк. |
Композиции, содержащие химерные молекулы ospa и способы их применения
|
CA2879939A1
(en)
|
2012-08-06 |
2014-02-13 |
Glaxosmithkline Biologicals S.A. |
Novel method
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
US10232035B2
(en)
|
2012-09-14 |
2019-03-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Conditionally replication deficient herpes virus and use thereof in vaccines
|
US9764027B2
(en)
|
2012-09-18 |
2017-09-19 |
Glaxosmithkline Biologicals Sa |
Outer membrane vesicles
|
CN104582718B
(zh)
|
2012-10-03 |
2017-10-24 |
诺华股份有限公司 |
免疫原性组合物
|
WO2014061749A1
(ja)
|
2012-10-18 |
2014-04-24 |
東亞合成株式会社 |
2型tnf受容体の発現を抑制する合成ペプチド及びその利用
|
WO2014083060A2
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Pseudomonas antigens and antigen combinations
|
EP2968521A2
(en)
|
2013-03-15 |
2016-01-20 |
GlaxoSmithKline Biologicals S.A. |
Vaccine
|
AU2014229561B2
(en)
|
2013-03-15 |
2018-06-07 |
Keith Alan Charlton |
Self-assembling synthetic proteins
|
CA2907571A1
(en)
|
2013-03-26 |
2014-10-02 |
The Pirbright Institute |
Stabilised fmdv capsids
|
US9907846B2
(en)
|
2013-04-01 |
2018-03-06 |
Mx Adjuvac Ab |
Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
|
MX370573B
(es)
|
2013-04-18 |
2019-12-17 |
Immune Design Corp |
Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
SG11201600709TA
(en)
|
2013-08-05 |
2016-02-26 |
Glaxosmithkline Biolog Sa |
Combination immunogenic compositions
|
EP3613430A2
(en)
|
2013-10-11 |
2020-02-26 |
Servizo Galego De Saúde (Sergas) |
Live attenuated vaccines
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
JP2017501162A
(ja)
|
2013-12-16 |
2017-01-12 |
ゾエティス・サービシーズ・エルエルシー |
ヘンドラ及びニパウイルスg糖タンパク質免疫原性組成物
|
EP3915579A1
(en)
|
2013-12-31 |
2021-12-01 |
Infectious Disease Research Institute |
Single vial vaccine formulations
|
CA2942450A1
(en)
|
2014-03-26 |
2015-10-01 |
Glaxosmithkline Biologicals S.A. |
Mutant staphylococcal antigens
|
US10813984B2
(en)
|
2014-04-24 |
2020-10-27 |
Rhode Island Hospital |
Aspartate-β-hydroxylase induces epitope-specific T cell responses in tumors
|
CA2951430A1
(en)
|
2014-06-13 |
2015-12-17 |
Glaxosmithkline Biologicals Sa |
Immunogenic combinations
|
US9790509B2
(en)
|
2014-07-18 |
2017-10-17 |
Oregon Health & Science University |
5′-triphosphate oligoribonucleotides
|
JP6820830B2
(ja)
|
2014-07-18 |
2021-01-27 |
ユニヴァーシティ オブ ワシントン |
がんワクチン組成物およびその使用方法
|
CN104250640A
(zh)
|
2014-08-22 |
2014-12-31 |
普莱柯生物工程股份有限公司 |
猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用
|
AU2015310932B2
(en)
|
2014-09-03 |
2018-11-22 |
Intervet International B.V. |
Attenuated bovine coronavirus and related vaccines
|
BR112017006620B1
(pt)
|
2014-10-03 |
2023-12-26 |
Intervet International B.V |
Vacina, métodos para a preparação de uma vacina e para reduzir infecção por reovírus aviário, composição, e, usos de material antigênico e de uma vacina
|
CA2963437A1
(en)
|
2014-10-15 |
2016-04-21 |
Xenothera |
Composition with reduced immunogenicity
|
WO2016140702A1
(en)
|
2015-03-03 |
2016-09-09 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces |
Display platform from bacterial spore coat proteins
|
CN111560355A
(zh)
|
2015-03-20 |
2020-08-21 |
普莱柯生物工程股份有限公司 |
一种猪伪狂犬病病毒致弱方法、及其致弱的病毒株、疫苗组合物和应用
|
US10954492B2
(en)
|
2015-06-10 |
2021-03-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Processes for production and purification of nucleic acid-containing compositions
|
MX2018002728A
(es)
|
2015-09-03 |
2018-09-05 |
Novavax Inc |
Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
|
CN105770887A
(zh)
*
|
2016-03-04 |
2016-07-20 |
邓招红 |
一种用于hbv疫苗的佐剂及其制备方法
|
GB2551984B
(en)
|
2016-06-30 |
2019-01-16 |
Pharmaq As |
Fish virus
|
CA3153265A1
(en)
|
2016-08-17 |
2018-02-22 |
Pharmaq As |
Sea lice vaccine
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
US11084850B2
(en)
|
2016-12-16 |
2021-08-10 |
The Pirbright Institute |
Recombinant prefusion RSV F proteins and uses thereof
|
MX2020000636A
(es)
|
2017-07-18 |
2020-08-20 |
In3Bio Ltd |
Proteinas sinteticas y usos terapeuticos de las mismas.
|
WO2019051149A1
(en)
|
2017-09-08 |
2019-03-14 |
Infectious Disease Research Institute |
LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
|
CA3092984A1
(en)
|
2018-03-19 |
2019-09-26 |
Novavax, Inc. |
Multivalent influenza nanoparticle vaccines
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
JP2021534761A
(ja)
|
2018-08-23 |
2021-12-16 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性タンパク質および組成物
|
CN114340665A
(zh)
|
2019-05-25 |
2022-04-12 |
传染病研究所 |
用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
|
CA3144845A1
(en)
|
2019-06-25 |
2020-12-30 |
In3Bio Ltd. |
Stabilized chimeric synthetic proteins and therapeutic uses thereof
|
US20220396797A1
(en)
|
2019-11-15 |
2022-12-15 |
Infectious Disease Research Institute |
Rig-i agonist and adjuvant formulation for tumor treatment
|
US10953089B1
(en)
|
2020-01-27 |
2021-03-23 |
Novavax, Inc. |
Coronavirus vaccine formulations
|
EP3922255A1
(en)
|
2020-06-10 |
2021-12-15 |
Prokarium Limited |
Cancer therapy
|
IL303334A
(en)
|
2020-12-02 |
2023-07-01 |
Glaxosmithkline Biologicals Sa |
The perfect fimh by a donor strand
|
CA3203043A1
(en)
|
2020-12-23 |
2022-06-30 |
Odile DUVAUX |
Composition of pig polyclonal antibody for its use to treat and/or prevent antibody-dependent macrophage pro-inflammatory cytokine release in a passive anti-infectious immunotherap
|
EP4124342A1
(en)
|
2021-07-28 |
2023-02-01 |
Prokarium Limited |
Cancer therapy with live attenuated bacteria
|
WO2023079528A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
|
WO2023114727A1
(en)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
GB2622559A
(en)
|
2022-05-10 |
2024-03-27 |
Johan Frostegaard |
Compositions, methods and uses
|
WO2023225458A1
(en)
|
2022-05-16 |
2023-11-23 |
Zoetis Services Llc |
Vaccines against moritella viscosa
|
GB202209588D0
(en)
|
2022-06-29 |
2022-08-10 |
Plant Bioscience Ltd |
Methods and compositions
|
GB202215134D0
(en)
|
2022-10-13 |
2022-11-30 |
Prokarium Ltd |
Composition
|
GB202215576D0
(en)
|
2022-10-21 |
2022-12-07 |
Prokarium Ltd |
Circuit
|